Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial
Paolo De Simone, Herold J. Metselaar, Lutz Fischer, Jérôme Dumortier, Karim Boudjema, Jean Hardwigsen, Lionel Rostaing, Luciano De Carlis, Faouzi Saliba, Frederik Nevens – 29 September 2009 – Calcineurin inhibitors (CNIs) contribute to renal dysfunction following liver transplantation. This prospective, randomized, multicenter, 6‐month study (with an additional 6 months of follow‐up) evaluated whether everolimus with CNI reduction or discontinuation would improve renal function in maintenance liver transplant recipients experiencing CNI‐related renal impairment.